This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ESMO 2023
ESMO 2023
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ESMO 2023 Prostate Cancer
Viewing 1-20 of 66 articles
ESMO 2023: Delineating Staging Pelvic Lymph Node Dissection Before Radiotherapy and Positioning Primary Prostatectomy
ESMO 2023: How Much Systemic Treatment Is Needed and How Long?
ESMO 2023: Dose Intensification and Field Expansion of External Beam Radiation Therapy
ESMO 2023: Tolerance and Long-Term Side-Effects
ESMO 2023: Usefulness and Limitations of PSMA Imaging/PET in High-Risk Localized Disease
ESMO 2023: Patient-Reported Outcomes in Men with mCRPC and HRR Mutations Receiving Talazoparib + Enzalutamide vs Placebo + Enzalutamide: Results from the Phase 3 TALAPRO-2 Study
ESMO 2023: Application of Novel Machine Learning Model in 68Ga-PSMA-11 PET/CT – Predicting Survival in Oligometastatic Prostate Cancer Patients
ESMO 2023: APEX-01: First-in-Human Phase 1/2 Study of ARX517, an Anti-PSMA ADC, in Patients with mCRPC
ESMO 2023: Impact of Intensified Androgen Deprivation Therapy in the Metastatic Castration-Sensitive Prostate Cancer Setting on Metastatic Castration-Resistant Prostate Cancer Disease Characteristics and Survival Outcomes
ESMO 2023: How to Best Integrate Biology
ESMO 2023: Talazoparib plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer: Subgroup Analyses of the All-Comers Cohort from TALAPRO-2 by HRR Status
ESMO 2023: Exploration of Germline vs Somatic Origin of Homologous Recombination Repair Gene Alterations and Potential Associations with Anti-Tumor Activity in the HRR-Deficient Population from TALAPRO-2
ESMO 2023: Real World Treatment Patterns of Metastatic Prostate Cancer with Enhanced Access to Homologous Recombination Repair Genomic Testing and PARP Inhibitors
ESMO 2023: Efficacy of Niraparib and Abiraterone Acetate + Prednisone in Homologous Recombination Repair Gene-Altered Metastatic Castration-Resistant Prostate Cancer by Tissue And/or Plasma Assays in the MAGNITUDE Trial
ESMO 2023: PSMAfore Discussant: Using Clinical Intelligence to Define First Line mCRPC Therapy
ESMO 2023: Next Generation Imaging: How Does It Change the Evidence Seen in Trials?
ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer
ESMO 2023: Phase 1/2 Study of Bavdegalutamide, a PROTAC Androgen Receptor Degrader, in mCRPC: Radiographic Progression-Free Survival in Patients with AR Ligand-Binding Domain Mutations
ESMO 2023: Treatment Patterns Among Novel Hormonal Therapy-experienced Patients with mCRPC
ESMO 2023: Exposure-Safety Analyses of Talazoparib in Combination of Enzalutamide in Patients with mCRPC in TALAPRO-2 Trial
1
2
3
4
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free